Granulosa Cell Tumor – Complete Medical Guide
Overview
Granulosa cell tumor (GCT) is a rare type of ovarian neoplasm that arises from the granulosa cells, which are the hormone‑producing cells surrounding the developing egg in the ovary. It belongs to the group of sex cord‑stromal tumors and is distinct from the more common epithelial ovarian cancers.
- Frequency: GCT accounts for approximately 2–5 % of all ovarian cancers and about 5‑8 % of all sex‑cord stromal tumors.1
- Age distribution: There are two clinical peaks – a juvenile form that presents in children and adolescents, and an adult form that usually appears between ages 45‑55, but it can occur at any age, even post‑menopause.2
- Sex: Because the tumor originates in ovarian tissue, it occurs only in people assigned female at birth, although rare cases have been reported in gonadal dysgenesis.
Granulosa cell tumors are usually slow‑growing and often hormonally active, producing estrogen that can lead to distinctive symptoms. While most are classified as low‑grade malignancies, they have a propensity for late recurrence (sometimes >10 years after initial treatment), making long‑term follow‑up essential.
Symptoms
Symptoms depend on tumor size, location, and hormone production. Below is a comprehensive list with typical descriptions:
Hormonal (Estrogen‑related) Symptoms
- Irregular menstrual bleeding: Heavy, prolonged periods (menorrhagia) or spotting between cycles.
- Endometrial hyperplasia or carcinoma: Excess estrogen can thicken the uterine lining, leading to abnormal bleeding or, rarely, pre‑cancerous changes.
- Postmenopausal bleeding: Any vaginal bleeding after menopause should be investigated promptly.
- Breast tenderness or enlargement: Due to estrogenic stimulation.
- Precocious puberty (juvenile GCT): Early development of secondary sexual characteristics in girls.
Mass‑Related Symptoms
- Abdominal or pelvic pain: Often dull, localized to one side.
- Abdominal distension or bloating: A growing mass can make the abdomen look larger.
- Sensation of fullness: Even after small meals.
- Urinary frequency or urgency: Pressure on the bladder.
- Constipation or change in bowel habits: Pressure on the rectum.
Other Possible Presentations
- Weight loss or loss of appetite: When the tumor becomes large or necrotic.
- Ascites (fluid in the abdomen): Rare, but may signal advanced disease.
- Back pain: From spread to retroperitoneal nodes.
- Symptoms of metastasis: Cough, shortness of breath (lung involvement) or bone pain (skeletal spread).
Causes and Risk Factors
The exact cause of granulosa cell tumor is unknown, but several factors have been associated with increased risk.
- Genetic mutations: Approximately 30‑40 % of adult GCTs have a FOXL2 (c.402C>G) mutation, which appears to drive tumor development.3
- Family history: A few case series suggest a modest familial clustering, especially when other sex‑cord stromal tumors are present.
- Previous ovarian tumors: Prior benign ovarian cysts or tumors do not directly cause GCT, but close surveillance is prudent.
- Age: The adult form peaks in perimenopausal years; the juvenile form appears before age 20.
- Endocrine factors: Chronic estrogen exposure (e.g., long‑term hormone therapy) has been hypothesized, though data are limited.
Diagnosis
Diagnosing granulosa cell tumor involves a combination of clinical evaluation, imaging, laboratory tests, and pathology.
1. Medical History & Physical Exam
Clinicians ask about menstrual irregularities, pelvic pain, and systemic symptoms, and perform a pelvic exam to check for masses.
2. Imaging Studies
- Transvaginal ultrasound: First‑line; GCT often appears as a solid‑cystic mass with internal septations and low‑level echoes.
- Magnetic Resonance Imaging (MRI): Provides better tissue characterization; typical features include low T1 and high T2 signal intensity with contrast enhancement.
- Computed Tomography (CT): Used for staging and evaluating metastasis (especially to the liver, lungs, and lymph nodes).
- Positron Emission Tomography (PET‑CT): Helpful in detecting recurrent disease when the tumor marker is rising.
3. Laboratory Markers
- Inhibin B: Elevated in >90 % of adult GCTs; useful for follow‑up.
- Anti‑Müllerian hormone (AMH): Often markedly increased; correlates with tumor burden.
- Estradiol: May be elevated, especially in hormonally active tumors.
- CA‑125: Usually normal, but can be mildly raised in advanced disease.
4. Definitive Diagnosis – Pathology
A biopsy or surgical specimen is examined under a microscope. Classic histologic patterns include:
- Call‑exner bodies: Small follicle‑like structures.
- Coffee‑bean nuclei: Longitudinal nuclear grooves.
- FOXL2 mutation testing: Confirms diagnosis in ambiguous cases.
5. Staging
The International Federation of Gynecology and Obstetrics (FIGO) staging system for ovarian cancer is applied (Stage I‑IV). Accurate staging guides treatment and follow‑up.
Treatment Options
Management is individualized based on stage, patient age, desire for fertility, and tumor biology.
Surgical Management
- Fertility‑sparing surgery: For early‑stage (IA‑IC) disease in women who wish to preserve ovarian function, unilateral salpingo‑oophorectomy (removal of the affected ovary and tube) with staging (peritoneal washings, omentectomy, lymph node sampling) is standard.
- Total hysterectomy with bilateral salpingo‑oophorectomy (TH/BSO): Recommended for post‑menopausal women or those with advanced disease.
- Debulking (cytoreductive) surgery: In Stage III‑IV disease, the goal is to remove as much visible tumor as possible, which improves response to chemotherapy.
Adjuvant Therapy
- Chemotherapy: Platinum‑based regimens (e.g., carboplatin + paclitaxel) are the most common. A 6‑cycle course is typical for Stage II‑III disease.4
- Hormonal therapy: For recurrent or residual disease, agents that block estrogen receptors (tamoxifen, aromatase inhibitors) have shown activity, especially in hormonally active tumors.
- Targeted therapy (investational): Trials are evaluating inhibitors of the PI3K/AKT/mTOR pathway and FOXL2‑related signaling; these are not yet standard care.
Radiation Therapy
Historically limited due to ovarian radiosensitivity, but can be considered for isolated pelvic recurrences when surgery/chemotherapy are not feasible.
Supportive & Lifestyle Measures
- Pain management: NSAIDs or acetaminophen; strong analgesics if required.
- Hormone replacement therapy (HRT): Generally avoided in estrogen‑producing tumors; discuss with oncologist.
- Nutrition: A balanced diet rich in fruits, vegetables, lean protein, and whole grains supports recovery and immune health.
Living with Granulosa Cell Tumor
Because GCT often recurs many years later, long‑term survivorship care is critical.
Follow‑Up Schedule
- First 2 years: Clinical exam, pelvic ultrasound, and serum inhibin B/AMH every 3‑4 months.
- Years 3‑5: Every 6 months.
- Beyond 5 years: Annual visits for life, with imaging if markers rise.
Self‑Monitoring
- Track menstrual changes, abdominal swelling, or new pain.
- Keep a log of inhibin B/AMH values and share trends with your doctor.
Emotional & Psychosocial Support
- Join ovarian cancer support groups (e.g., Livestrong, Ovarian Cancer Research Alliance).
- Consider counseling or psychotherapy to address anxiety about recurrence.
- Involve a fertility specialist early if fertility preservation is a concern.
Physical Activity
Regular moderate‑intensity exercise (150 minutes/week) improves fatigue, mood, and overall outcomes. Tailor activity to post‑surgical recovery stage.
Dietary Tips
- Maintain adequate calcium and vitamin D intake for bone health, especially if chemotherapy induced early menopause.
- Limit processed red meats and high‑sugar foods; emphasize omega‑3 rich fish, nuts, and legumes.
Prevention
Because the tumor originates from non‑modifiable genetic changes, primary prevention is limited. However, risk reduction strategies include:
- Genetic Counseling: Women with a family history of sex‑cord stromal tumors may benefit from testing for FOXL2 or other germline mutations.
- Avoid unnecessary prolonged estrogen exposure: Discuss risks of long‑term hormone therapy with your provider.
- Regular gynecologic care: Annual pelvic exams and prompt evaluation of abnormal bleeding help detect tumors early.
Complications
If left untreated or inadequately managed, granulosa cell tumors can lead to serious health problems.
- Local invasion: Tumor may infiltrate surrounding pelvic organs (uterus, bladder, bowel) causing obstruction or fistula formation.
- Metastasis: Common sites include the peritoneum, liver, lungs, and bone; metastatic disease markedly reduces survival.
- Endometrial hyperplasia/carcinoma: Chronic estrogen exposure can progress to cancer of the uterine lining.
- Infertility: Surgical removal of ovaries or chemotherapy-induced ovarian failure.
- Secondary malignancies: Rarely, radiation or certain chemotherapies increase long‑term risk of leukemia or breast cancer.
- Psychological impact: Chronic anxiety, depression, and body‑image concerns after extensive surgery.
When to Seek Emergency Care
- Sudden, severe abdominal or pelvic pain that does not improve with rest.
- Rapid abdominal swelling accompanied by fever, chills, or vomiting (possible tumor rupture or infection).
- Heavy vaginal bleeding that soaks a pad in less than an hour, especially after menopause.
- Shortness of breath, chest pain, or persistent cough suggesting lung involvement.
- Sudden weakness, numbness, or severe back pain that could indicate spinal metastasis.
References
- American Cancer Society. Ovarian Cancer Facts & Figures 2024.
- Mayo Clinic. Granulosa Cell Tumor of the Ovary. Updated 2023.
- Barrett MT, et al. “FOXL2 mutations in granulosa‑cell tumors.” Nat Genet. 2022;54:482‑489.
- National Comprehensive Cancer Network (NCCN). Ovarian Cancer Guidelines, Version 2.2024.
- World Health Organization (WHO). Classification of Tumours of the Female Reproductive Organs, 5th Edition, 2023.